Biomea Fusion Inc
NASDAQ:BMEA
Biomea Fusion Inc
NASDAQ:BMEA
Price:
1.26
USD
-2.33%
Market Closed
Market Cap:
$91.1m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Biomea Fusion Inc
NASDAQ:BMEA
|
US |
|
C
|
China Shenhua Energy Co Ltd
XMUN:IKF
|
CN |
|
G
|
Gold Fields Ltd
JSE:GFI
|
ZA |
|
CTS Corp
F:XT1
|
US |
|
W
|
Western Digital Corp
DUS:WDC
|
US |
|
A
|
Align Technology Inc
F:AFW
|
US |
|
E
|
Endeavour Silver Corp
XHAM:EJD
|
CA |
|
Brown & Brown Inc
NYSE:BRO
|
US |
|
DSM-Firmenich AG
SIX:DSFIR
|
CH |
|
H
|
H & M Hennes & Mauritz AB
DUS:HMSB
|
SE |
|
Lindblad Expeditions Holdings Inc
NASDAQ:LIND
|
US |
|
Healthequity Inc
NASDAQ:HQY
|
US |
| Metric | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| 200k | 61.7m | 145.7m | 111.9m | 176.9m | 58.3m | 55.8m | |
| 200k | 61.7m | 145.7m | 111.9m | 176.9m | 58.3m | 55.8m | |
| — | — | 27.8m | 1.2m | 0 | — | — | |
| 0 | 500k | 3m | 4.8m | 2.3m | 10.1m | 2.2m | |
| 300k | 62.2m | 176.6m | 117.8m | 179.2m | 68.3m | 58.1m | |
| 0 | 300k | 5.7m | 8m | 14.9m | 10.6m | 153k | |
| 0 | 300k | 5.7m | 8m | 14.9m | 10.6m | 153k | |
| 0 | 0 | (300k) | (900k) | (2.4m) | (4.2m) | (1m) | |
| — | — | 1.9m | 0 | 0 | — | — | |
| 0 | 0 | 1.6m | 3.5m | 5.9m | 988k | 369k | |
| 300k | 62.5m | 185.7m | 129.3m | 199.9m | 79.9m | 58.6m | |
| 300k | 700k | 1.3m | 6.8m | 6.9m | 12.9m | 3.2m | |
| 0 | 900k | 2.8m | 11.6m | 15.8m | 8.5m | 7.7m | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| — | — | 500k | 600k | 192k | 203k | 169k | |
| 300k | 1.6m | 4.6m | 19.1m | 22.9m | 21.7m | 11.1m | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| — | — | 2.3m | 1.7m | 7.8m | 6.7m | 17.9m | |
| 300k | 1.6m | 6.9m | 20.8m | 30.7m | 28.4m | 29m | |
| 0 | 55.7m | 0 | 0 | 4k | 4k | 7k | |
| (2.9m) | (8.2m) | (49.7m) | (131.6m) | (248.8m) | (387.3m) | (449m) | |
| 2.8m | 13.3m | 228.5m | 240.1m | 418.1m | 438.8m | 478.6m | |
| — | — | 0 | 0 | 0 | — | — | |
| 0 | 60.9m | 178.8m | 108.5m | 169.2m | 51.6m | 29.6m | |
| 300k | 62.5m | 185.7m | 129.3m | 199.9m | 79.9m | 58.6m | |
| 28.8m | 28.8m | 29.1m | 29.6m | 35.9m | 36.3m | 72.3m |
A growing testing platform nearing break-even but still reliant on external funding
A pre-revenue clinical biotech funding rising trial costs through external capital
A cash-generative biotech transitioning from legacy MS to acquired growth platforms
